We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System
Read MoreHide Full Article
Merit Medical Systems, Inc. (MMSI - Free Report) recently announced the commercial launch of its FDA-approved Micro ACE Advanced Micro-Access System.
To accomplish successful micro-access in difficult situations, Micro ACE combines a unique combination of stiffness and resilience. The company also expects to file Micro ACE for CE mark designation soon.
Price Performance
For the past six months, MMSI’s shares have gained 7.5% compared with the industry’s rise of 6.7% The S&P 500 increased 19.0% in the same time frame.
Image Source: Zacks Investment Research
More on the News
The newest addition to Merit Medical’s Vascular arsenal of innovations is the Micro ACE system. A complete selection of percutaneous access and closure devices are included in the extensive portfolio. Micro ACE combines resilience and stiffness in the right amounts to enable micro-access in a variety of vascular anatomy.
Atherosclerotic blood arteries are narrowed, and interventional treatments using micro-access are frequently used to diagnose and open them. When plaque accumulates inside the arteries, an inflammatory disease known as atherosclerosis occurs.
The Micro ACE finds a balance between stiffness and flexibility to provide good resistance to kink and compression, making interventional treatments easier.
Furthermore, a special marker tip design provides better visibility under fluoroscopy for precise placement, which is essential at the beginning of a process.
Merit Medical is pursuing patents on Micro ACE technology in the United States and internationally.
Industry Prospects
Per a report by Grand View Research,the global vascular access devices market size was valued at $1.8 billion in 2022 and is expected to witness a growth rate of 5% from 2023 to 2030.
Patient demographics, such as the aging global population, the rising cancer prevalence, and the widespread metabolic, respiratory, and cardiovascular disorders will have a significant impact on market growth.
Given the market potential for vascular access devices, Merit Medical’s latest FDA-cleared Micro ACE Advanced Micro-Access System is likely to provide a significant boost to the company’s business.
Notable Developments
In February, the company announced the FDA approval for the SCOUT MD Surgical Guidance System. With the ability to target tumor sites in various dimensions for accurate excision and successful surgeries, the new guiding system represents a substantial development in the treatment of breast cancer. SCOUT MD adds to Merit Medical’s oncology portfolio.
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Cencora, Inc. (COR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 58.3% compared with the industry’s 18.9% rise in the past year.
Cardinal Health, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 51.9% compared with the industry’s 3.2% rise in the past year.
Cencora, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 9.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.7%.
Cencora’s shares have rallied 51.5% compared with the industry’s 3.6% rise in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System
Merit Medical Systems, Inc. (MMSI - Free Report) recently announced the commercial launch of its FDA-approved Micro ACE Advanced Micro-Access System.
To accomplish successful micro-access in difficult situations, Micro ACE combines a unique combination of stiffness and resilience. The company also expects to file Micro ACE for CE mark designation soon.
Price Performance
For the past six months, MMSI’s shares have gained 7.5% compared with the industry’s rise of 6.7% The S&P 500 increased 19.0% in the same time frame.
Image Source: Zacks Investment Research
More on the News
The newest addition to Merit Medical’s Vascular arsenal of innovations is the Micro ACE system. A complete selection of percutaneous access and closure devices are included in the extensive portfolio. Micro ACE combines resilience and stiffness in the right amounts to enable micro-access in a variety of vascular anatomy.
Atherosclerotic blood arteries are narrowed, and interventional treatments using micro-access are frequently used to diagnose and open them. When plaque accumulates inside the arteries, an inflammatory disease known as atherosclerosis occurs.
The Micro ACE finds a balance between stiffness and flexibility to provide good resistance to kink and compression, making interventional treatments easier.
Furthermore, a special marker tip design provides better visibility under fluoroscopy for precise placement, which is essential at the beginning of a process.
Merit Medical is pursuing patents on Micro ACE technology in the United States and internationally.
Industry Prospects
Per a report by Grand View Research,the global vascular access devices market size was valued at $1.8 billion in 2022 and is expected to witness a growth rate of 5% from 2023 to 2030.
Patient demographics, such as the aging global population, the rising cancer prevalence, and the widespread metabolic, respiratory, and cardiovascular disorders will have a significant impact on market growth.
Given the market potential for vascular access devices, Merit Medical’s latest FDA-cleared Micro ACE Advanced Micro-Access System is likely to provide a significant boost to the company’s business.
Notable Developments
In February, the company announced the FDA approval for the SCOUT MD Surgical Guidance System. With the ability to target tumor sites in various dimensions for accurate excision and successful surgeries, the new guiding system represents a substantial development in the treatment of breast cancer. SCOUT MD adds to Merit Medical’s oncology portfolio.
Merit Medical Systems, Inc. Price
Merit Medical Systems, Inc. price | Merit Medical Systems, Inc. Quote
Zacks Rank & Stocks to Consider
MMSI carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Cencora, Inc. (COR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 58.3% compared with the industry’s 18.9% rise in the past year.
Cardinal Health, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 51.9% compared with the industry’s 3.2% rise in the past year.
Cencora, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 9.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.7%.
Cencora’s shares have rallied 51.5% compared with the industry’s 3.6% rise in the past year.